Gregory Lip
Nature Reviews Drug Discovery 11,434 (2012).
doi:10.1038/nrd3752
The US Food and Drug Administration (FDA) approval of Boehringer Ingelheim’s dabigatran for stroke prevention in atrial fibrillation last year was a key success in a long hunt for oral anticoagulants. A year and a half on,however,the drug’s place in the anticoagulant armamentarium still remains unclear. The jury is out on how the direct thrombin inhibitor fares versus warfarin in the real-world setting,and how it stacks up against oral factor Xa inhibitors like Bayer’s rivaroxaban and Bristol-Myers Squibb/Pfizer’s apixaban (the FDA is due to rule on approval for apixaban in June). To answer these questions,Boehringer Ingelheim has now launched one of the world’s largest registries,GLORIA-AF,to follow the use of anticoagulants — including dabigatran and its competitors — in 56,000 patients. Co-chairing the steering committee of the study is Gregory Lip,a cardiologist at the University of Birmingham Centre for Cardiovascular Sciences,UK. He discusses the changing anticoagulant landscape with Asher Mullard.
Nature Reviews Drug Discovery –Issue –nature.com science feeds
